surpass cvot tirzepatide results SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Diabetes Distilled: “Twincretin” tirzepatide significantly

By mimicking the effects of both GLP-1 and GIP, tirzepatide has a powerful combined effect in your body

This specificity comes from growth hormone direct lipolytic action on visceral adipocytes, which express higher concentrations of growth hormone receptors than subcutaneous fat cells

Dosing Frequency: Once weekly (as prescribed)

Ideal Candidates for Tirzepatide Therapy Tirzepatide is intended for individuals who meet specific medical criteria for overweight or obesity, as well as those seeking medically supervised weight loss for aesthetic or health-related goals

Tirzepatide is administered as a once-weekly subcutaneous injection, with a recommended starting dose of 2.5 mg for both indications